



Batch No. :  
Exp. Date :

APVMA Approval No.: 57787/30T/0904  
Store below 30°C (Room temperature).

STORAGE:  
Store below 30°C (Room temperature).  
Dispose of empty container by wrapping with paper and putting in garbage.

DISPOSAL:  
If poisoning occurs, contact a doctor or Poisons Information Centre.  
Phone Australia 131126.

FIRST AID:  
For oral administration.

DOSAGE AND ADMINISTRATION:  
Tumour promoting effect in target organs with oestrogen receptors (mammary gland).

CONTRAINDICATIONS:  
Do not use in intact bitches as the efficacy has only been established in ovariectomised bitches.

DIRECTIONS FOR USE:  
Animals showing a polytra-polydipsia should not be treated with INCURIN® per dog. The incidence is about 5-9% and/or attractiveness to males and vomiting have been observed at the highest recommended dose of 2 mg

Excresion is primarily via the bile. Use with caution in animals with liver disease.  
SIDE EFFECTS:  
High doses of oestrogen may have a particularly with long term use.

Alpecia is a potential side effect. In rare cases vaginal bleeding occurred. Lowering the dose. These effects are reversible after

APVMA Approval No.: 57787/30T/0904  
Store below 30°C (Room temperature).

STORAGE:  
Store below 30°C (Room temperature).  
Dispose of empty container by wrapping with paper and putting in garbage.

DISPOSAL:  
If poisoning occurs, contact a doctor or Poisons Information Centre.  
Phone Australia 131126.

FIRST AID:  
For oral administration.

DOSAGE AND ADMINISTRATION:  
Tumour promoting effect in target organs with oestrogen receptors (mammary gland).

CONTRAINDICATIONS:  
Do not use in intact bitches as the efficacy has only been established in ovariectomised bitches.

DIRECTIONS FOR USE:  
Animals showing a polytra-polydipsia should not be treated with INCURIN® per dog. The incidence is about 5-9% and/or attractiveness to males and vomiting have been observed at the highest recommended dose of 2 mg

Excresion is primarily via the bile. Use with caution in animals with liver disease.  
SIDE EFFECTS:  
High doses of oestrogen may have a particularly with long term use.

Alpecia is a potential side effect. In rare cases vaginal bleeding occurred. Lowering the dose. These effects are reversible after

APVMA Approval No.: 57787/30T/0904  
Store below 30°C (Room temperature).

STORAGE:  
Store below 30°C (Room temperature).  
Dispose of empty container by wrapping with paper and putting in garbage.

DISPOSAL:  
If poisoning occurs, contact a doctor or Poisons Information Centre.  
Phone Australia 131126.

FIRST AID:  
For oral administration.

DOSAGE AND ADMINISTRATION:  
Tumour promoting effect in target organs with oestrogen receptors (mammary gland).

CONTRAINDICATIONS:  
Do not use in intact bitches as the efficacy has only been established in ovariectomised bitches.

DIRECTIONS FOR USE:  
Animals showing a polytra-polydipsia should not be treated with INCURIN® per dog. The incidence is about 5-9% and/or attractiveness to males and vomiting have been observed at the highest recommended dose of 2 mg

Excresion is primarily via the bile. Use with caution in animals with liver disease.  
SIDE EFFECTS:  
High doses of oestrogen may have a particularly with long term use.

049573A  
5150 / 328

**INCURIN®**

ACTIVE CONSTITUENT: OESTRIOL, 1 mg/TABLET



**PRESCRIPTION ANIMAL REMEDY  
KEEP OUT OF REACH OF CHILDREN  
FOR ANIMAL TREATMENT ONLY  
INCURIN®**

ACTIVE CONSTITUENT:  
OESTRIOL, 1 mg/TABLET

An aid in the treatment of hormone-responsive urinary incontinence due to sphincter mechanism incompetence in ovariectomised bitches.

30 Tablets



INTERVET AUSTRALIA PTY LIMITED  
91-105 Harpin Street, BENDIGO EAST VIC 3550  
Phone: (03) 5440 9888


**INCURIN®**  
ACTIVE CONSTITUENT: OESTRIOL, 1 mg/TABLET



090605A 0033.880.2960

**PRESCRIPTION ANIMAL REMEDY  
KEEP OUT OF REACH OF CHILDREN  
FOR ANIMAL TREATMENT ONLY**

# INCURIN®



**ACTIVE CONSTITUENT:  
OESTRIOL, 1 mg/TABLET**

An aid in the treatment of hormone-responsive urinary incontinence due to sphincter mechanism incompetence in ovariohysterectomised bitches.

#### **DIRECTIONS FOR USE:**

##### **CONTRAINDICATIONS:**

Do not use in intact bitches, as the efficacy has only been established in ovariohysterectomised bitches.

Animals showing a polyuria-polydipsia syndrome should not be treated with INCURIN®.

Excretion is primarily via the bile. Use with caution in animals with liver disease.

##### **SIDE EFFECTS:**

Oestrogenic effects such as swollen vulva, swollen mammary glands and/or attractiveness to males and vomiting have been observed at the highest recommended dose of 2 mg per dog.

The incidence is about 5-9%. These effects are reversible after lowering the dose.

In rare cases vaginal bleeding occurred.

High doses of oestrogen may have a tumour-promoting effect in target organs with oestrogen receptors (mammary gland).

Alopecia is a potential side effect, particularly with long term use.

##### **DOSAGE AND ADMINISTRATION:**

A relationship between final effective dose and bodyweight has not been established and therefore the dose has to be determined for each dog on an individual basis.

INCURIN® is intended for oral administration.

There is individual variation in the response of bitches to Oestriol. The objective is therefore to identify the minimum effective dose regimen for each patient. The following approach is advised:

Start treatment with 1 tablet (1 mg Oestriol) once daily for 7 days.

If treatment is not successful, increase the dose to 2 tablets (2 mg Oestriol) once daily for 7 days. No more than 2 tablets (2 mg Oestriol) per dog per day should be used. If no response to treatment is obtained, the diagnosis should be reconsidered in order to investigate other causes for the incontinence such as neurologic disorders, bladder neoplasia, etc.

If the initial treatment of 1 tablet (1 mg Oestriol) once daily is successful, lower the dose to half a tablet (0.5 mg Oestriol) once daily for 7 days.

The minimum dose given should not be less than 0.5 mg per dog per day.

Once the effective daily dose has been established, treatment every second or third day may be tried.

##### **GENERAL DIRECTIONS:**

Oestriol is a short-acting natural oestrogen.

After oral administration of multiple doses no accumulation occurs. In the target animal safety study and the clinical trials, including long-term treatment, no signs of bone marrow suppression were observed.

This is probably due to the short-acting oestrogenic character of Oestriol.

##### **FIRST AID:**

If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131126.

##### **DISPOSAL:**

Dispose of empty container by wrapping with paper and putting in garbage.

##### **STORAGE:**

Store below 30°C (Room temperature).

APVMA Approval No.: 57787/0904

090605A 7.04

INTERVET AUSTRALIA PTY LIMITED

91-105 Harpin Street

BENDIGO EAST VIC 3550

Phone: (03) 5440 9888